Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
Rhea-AI Summary
Exicure (Nasdaq:XCUR) received a Nasdaq Listing Qualifications notice on May 28, 2026 for non-compliance with Rule 5250(c)(1) due to a delayed Form 10-Q for Q1 2026. The delay stemmed from changes in financial reporting personnel and procedures. Exicure filed the Form 10-Q on May 29, 2026 and believes it has regained compliance.
Positive
- Delayed Q1 2026 Form 10-Q filed on May 29, 2026
- Company believes Nasdaq Listing Rule 5250(c)(1) compliance has been regained
Negative
- Nasdaq delinquency notice received May 28, 2026 for late Q1 2026 Form 10-Q
- Non-compliance linked to changes in financial reporting personnel and procedures
News Market Reaction – XCUR
In the Jun 2 session, XCUR declined 6.61%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | Co-development deal | Positive | +0.1% | Co-development agreement for burixafor in multiple indications with Adbiotech. |
| Mar 25 | Full-year earnings | Negative | +0.0% | Full-year 2025 results highlighting liquidity shortfall and going-concern risks. |
| Feb 05 | Phase 2 publication | Positive | +4.4% | Publication of Phase 2 burixafor data showing rapid stem cell mobilization. |
| Jan 21 | Clinical data presentation | Positive | +2.3% | Announcement of Phase 2 burixafor data presentation with high primary endpoint success. |
| Dec 08 | Topline Phase 2 data | Positive | +36.8% | Positive topline Phase 2 burixafor results with strong mobilization and tolerability. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical and partnership news has typically aligned with upward moves, including a notable 36.77% jump on strong Phase 2 data, while negative liquidity/earnings updates have not always produced immediate downside.
Over the past six months, Exicure has focused on its burixafor (GPC-100) program and strategic repositioning. Multiple Phase 2 data disclosures in late 2025 and early 2026 showed high CD34+ cell mobilization rates and generally favorable safety, with shares reacting positively, especially to the December 2025 topline update. A March 2026 full-year 2025 results disclosure highlighted severe liquidity constraints and going-concern risks but saw no immediate price move. The current Nasdaq delinquency notice, followed by timely Form 10-Q filing, fits into ongoing governance and reporting remediation efforts.
Key Terms
nasdaq listing rule 5250(c)(1) regulatory
form 10-q regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 28, 2026 indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2026.
The delay was primarily due to additional time required following changes in the Company’s financial reporting personnel and related filing procedures.
The Company filed its Quarterly Report on Form 10-Q for the three months ended March 31, 2026 with the Securities and Exchange Commission on May 29, 2026 and believes that it has regained compliance with Nasdaq Listing Rule 5250(c)(1).
About Exicure, Inc.
Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value. In January 2025, it acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases. The Company’s lead program in development is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. For more information, visit www.exicuretx.com.
Cautionary Note Regarding Forward Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements related to the Company’s review and analysis in connection with the Form 10-Q and the Company’s expectations with respect to its financial results for the three months ended March 31, 2026 and the definitive filing date of the Form 10-Q. Forward-looking statements are based on management’s current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. For a discussion of risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 25, 2026, as updated by the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information or to publicly announce the results of any revisions to any of such statements to reflect future events or developments, except as required by law.
Media Contact:
Exicure, Inc.
pr@exicuretx.com
